Prognostic significance of long non-coding RNA five prime to XIST in various cancers
Background
To observe the clinicopathological and prognostic value of long non-coding RNA five prime to X inactive specific transcript (lncFTX) in multiple tumors.
Methods
Eligible studies for lncFTX were identified by searching PubMed, Embase, Web of Science and Cochrane Library databases from inception to December 01, 2020. Stata 12.0 software was used to calculate the odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (95% CI). We used The Cancer Genome Atlas (TCGA) dataset to further investigate the differential expression and prognostic value of lncFTX.
Results
We included 11 studies involving a total of 1633 patients. The results showed that the expression of lncFTX was positively associated with advanced TNM stage (III-IV versus I-II) (OR = 2.30, 95% CI: 1.74–3.03, P < 0.05), lymph nodes metastasis (OR = 3.01, 95% CI: 2.00–4.52, P < 0.05), distant metastasis (OR = 3.68, 95% CI: 2.13–6.34, P < 0.05), and cancer mortality (HR = 1.83, 95% CI: 1.20–2.81, P < 0.05). However, the expression of lncFTX was not associated with tumor differentiation (poor differentiation versus well or moderate differentiation) and vessel invasion of cancer. Subgroup analysis showed that the higher lncFTX expression was associated with shorter overall survival in cancer patients, regardless of the sample size and cancer type. No publication bias was found, and the sensitivity analysis results suggested that the main findings were robust. Elevated expression and prognostic significance of FTX were confirmed using TCGA dataset.
Conclusions
This study found that the expression of lncFTX was positively associated with advanced tumor node metastasis (TNM) stage, lymph nodes, distant metastasis and, cancer mortality, suggesting that lncFTX might be a potential prognostic biomarker for tumors.
History
Publication title
BMC CancerVolume
22Article number
61Number
61Pagination
1-11ISSN
1471-2407Department/School
Menzies Institute for Medical ResearchPublisher
Biomed Central LtdPlace of publication
Middlesex House, 34-42 Cleveland St, London, England, W1T 4LbRights statement
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, (https://creativecommons.org/licenses/by/4.0/) which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.Repository Status
- Open